在清细胞细胞癌中HIF向治疗的演变
Borivoj Golijanin1, Kamil Malshy1, Sari Khaleel1
1The Minimally Invasive Urology Institute at The Miriam Hospital, Division of Urology, Lifespan Academic Medical Center, The Legorreta Cancer Center at Brown University, Warren Alpert Medical School of Brown University, Providence, RI 02906, United States.
清细胞细胞癌 (ccRCC) 的发病过程涉及VHL基因丢失,导致缺氧诱导因子 (HIF) 积累. 新型疗法现在针对HIF2α治疗这种常见的癌.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 清细胞细胞癌 (ccRCC) 是全球最常见的癌.
- 它的发展经常与VHL瘤抑制基因的丧失有关.
- 通常情况下,VHL会促进低氧诱导因子 (HIF) 的降解.
研究的目的:
- 审查HIF在ccRCC发病过程中的作用.
- 讨论针对HIF2α的新兴治疗策略.
- 探索ccRCC的新治疗机会.
主要方法:
- 关于ccRCC病原和治疗策略的文献综述.
- 对癌症发展中的VHL-HIF途径的分析.
- 目前和新型HIF2α向治疗的概述.
主要成果:
- 失去VHL功能导致HIF积累,特别是HIF2α.
- 过度积累的HIF2α驱动了ccRCC细胞的生存和增殖.
- 目前的疗法针对下游的HIF效应物或使用免疫疗法;新的方法针对上游的HIF.
结论:
- HIF2α是ccRCC病变发生的关键驱动因素.
- 准HIF2α是一个有前途的治疗途径.
- 对HIF重点治疗的进一步研究可以改善ccRCC治疗结果.
更多相关视频
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
05:36Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers
Tumor Immunotherapy
